nodes	percent_of_prediction	percent_of_DWPC	metapath
Ingenol Mebutate—PRKCA—nephron—kidney cancer	0.0649	0.359	CbGeAlD
Ingenol Mebutate—PRKCD—renal system—kidney cancer	0.0231	0.128	CbGeAlD
Ingenol Mebutate—PRKCD—cortex of kidney—kidney cancer	0.0217	0.12	CbGeAlD
Ingenol Mebutate—PRKCD—gonad—kidney cancer	0.0207	0.114	CbGeAlD
Ingenol Mebutate—PRKCA—nephron tubule—kidney cancer	0.014	0.0774	CbGeAlD
Ingenol Mebutate—PRKCA—renal system—kidney cancer	0.0127	0.0704	CbGeAlD
Ingenol Mebutate—PRKCA—kidney—kidney cancer	0.0123	0.068	CbGeAlD
Ingenol Mebutate—PRKCA—gonad—kidney cancer	0.0114	0.0631	CbGeAlD
Ingenol Mebutate—PRKCD—Azacitidine—Gemcitabine—kidney cancer	0.0104	1	CbGdCrCtD
Ingenol Mebutate—Eyelid oedema—Pazopanib—kidney cancer	0.0089	0.0552	CcSEcCtD
Ingenol Mebutate—Periorbital oedema—Sunitinib—kidney cancer	0.00749	0.0465	CcSEcCtD
Ingenol Mebutate—Eyelid oedema—Everolimus—kidney cancer	0.00703	0.0436	CcSEcCtD
Ingenol Mebutate—Eyelid oedema—Sunitinib—kidney cancer	0.00587	0.0364	CcSEcCtD
Ingenol Mebutate—Scab—Capecitabine—kidney cancer	0.00513	0.0319	CcSEcCtD
Ingenol Mebutate—Swelling—Temsirolimus—kidney cancer	0.00392	0.0243	CcSEcCtD
Ingenol Mebutate—Ulcer—Dactinomycin—kidney cancer	0.00296	0.0184	CcSEcCtD
Ingenol Mebutate—Nasopharyngitis—Pazopanib—kidney cancer	0.00291	0.0181	CcSEcCtD
Ingenol Mebutate—Infestation NOS—Temsirolimus—kidney cancer	0.00267	0.0165	CcSEcCtD
Ingenol Mebutate—Infestation—Temsirolimus—kidney cancer	0.00267	0.0165	CcSEcCtD
Ingenol Mebutate—Conjunctivitis—Temsirolimus—kidney cancer	0.00259	0.0161	CcSEcCtD
Ingenol Mebutate—Ulcer—Gemcitabine—kidney cancer	0.00251	0.0156	CcSEcCtD
Ingenol Mebutate—Infestation—Pazopanib—kidney cancer	0.00251	0.0156	CcSEcCtD
Ingenol Mebutate—Infestation NOS—Pazopanib—kidney cancer	0.00251	0.0156	CcSEcCtD
Ingenol Mebutate—Nasopharyngitis—Everolimus—kidney cancer	0.0023	0.0143	CcSEcCtD
Ingenol Mebutate—Eye disorder—Temsirolimus—kidney cancer	0.00224	0.0139	CcSEcCtD
Ingenol Mebutate—Eye disorder—Pazopanib—kidney cancer	0.00211	0.0131	CcSEcCtD
Ingenol Mebutate—Erythema—Temsirolimus—kidney cancer	0.00208	0.0129	CcSEcCtD
Ingenol Mebutate—Nasopharyngitis—Sorafenib—kidney cancer	0.002	0.0124	CcSEcCtD
Ingenol Mebutate—Infestation—Everolimus—kidney cancer	0.00198	0.0123	CcSEcCtD
Ingenol Mebutate—Infestation NOS—Everolimus—kidney cancer	0.00198	0.0123	CcSEcCtD
Ingenol Mebutate—Erythema—Pazopanib—kidney cancer	0.00196	0.0122	CcSEcCtD
Ingenol Mebutate—Conjunctivitis—Everolimus—kidney cancer	0.00193	0.012	CcSEcCtD
Ingenol Mebutate—Nasopharyngitis—Sunitinib—kidney cancer	0.00192	0.0119	CcSEcCtD
Ingenol Mebutate—Infestation NOS—Erlotinib—kidney cancer	0.00191	0.0119	CcSEcCtD
Ingenol Mebutate—Infestation—Erlotinib—kidney cancer	0.00191	0.0119	CcSEcCtD
Ingenol Mebutate—Conjunctivitis—Erlotinib—kidney cancer	0.00186	0.0115	CcSEcCtD
Ingenol Mebutate—Ulcer—Capecitabine—kidney cancer	0.00173	0.0107	CcSEcCtD
Ingenol Mebutate—Infestation NOS—Sorafenib—kidney cancer	0.00172	0.0107	CcSEcCtD
Ingenol Mebutate—Infestation—Sorafenib—kidney cancer	0.00172	0.0107	CcSEcCtD
Ingenol Mebutate—Infection—Temsirolimus—kidney cancer	0.00169	0.0105	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Temsirolimus—kidney cancer	0.00167	0.0103	CcSEcCtD
Ingenol Mebutate—Eye disorder—Everolimus—kidney cancer	0.00166	0.0103	CcSEcCtD
Ingenol Mebutate—Infestation—Sunitinib—kidney cancer	0.00166	0.0103	CcSEcCtD
Ingenol Mebutate—Infestation NOS—Sunitinib—kidney cancer	0.00166	0.0103	CcSEcCtD
Ingenol Mebutate—Swelling—Paclitaxel—kidney cancer	0.00164	0.0102	CcSEcCtD
Ingenol Mebutate—Eye disorder—Erlotinib—kidney cancer	0.00161	0.00996	CcSEcCtD
Ingenol Mebutate—Eye pain—Paclitaxel—kidney cancer	0.0016	0.00993	CcSEcCtD
Ingenol Mebutate—Infection—Pazopanib—kidney cancer	0.00159	0.00988	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Pazopanib—kidney cancer	0.00157	0.00975	CcSEcCtD
Ingenol Mebutate—Erythema—Everolimus—kidney cancer	0.00155	0.00962	CcSEcCtD
Ingenol Mebutate—Erythema—Erlotinib—kidney cancer	0.0015	0.00928	CcSEcCtD
Ingenol Mebutate—Eye disorder—Sunitinib—kidney cancer	0.00139	0.00862	CcSEcCtD
Ingenol Mebutate—Erythema—Sorafenib—kidney cancer	0.00135	0.00835	CcSEcCtD
Ingenol Mebutate—Swelling—Capecitabine—kidney cancer	0.00134	0.00834	CcSEcCtD
Ingenol Mebutate—Eye pain—Capecitabine—kidney cancer	0.00131	0.00815	CcSEcCtD
Ingenol Mebutate—Erythema—Sunitinib—kidney cancer	0.00129	0.00803	CcSEcCtD
Ingenol Mebutate—Nasopharyngitis—Paclitaxel—kidney cancer	0.00129	0.00801	CcSEcCtD
Ingenol Mebutate—Infection—Everolimus—kidney cancer	0.00126	0.0078	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Everolimus—kidney cancer	0.00124	0.0077	CcSEcCtD
Ingenol Mebutate—Erythema—Dactinomycin—kidney cancer	0.00123	0.0076	CcSEcCtD
Ingenol Mebutate—Infection—Erlotinib—kidney cancer	0.00121	0.00752	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Erlotinib—kidney cancer	0.0012	0.00743	CcSEcCtD
Ingenol Mebutate—Infestation NOS—Paclitaxel—kidney cancer	0.00111	0.00691	CcSEcCtD
Ingenol Mebutate—Infestation—Paclitaxel—kidney cancer	0.00111	0.00691	CcSEcCtD
Ingenol Mebutate—Ulcer—Doxorubicin—kidney cancer	0.00111	0.0069	CcSEcCtD
Ingenol Mebutate—Infection—Sorafenib—kidney cancer	0.00109	0.00677	CcSEcCtD
Ingenol Mebutate—Conjunctivitis—Paclitaxel—kidney cancer	0.00108	0.00671	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Sorafenib—kidney cancer	0.00108	0.00668	CcSEcCtD
Ingenol Mebutate—Headache—Temsirolimus—kidney cancer	0.00107	0.00661	CcSEcCtD
Ingenol Mebutate—Nasopharyngitis—Capecitabine—kidney cancer	0.00106	0.00658	CcSEcCtD
Ingenol Mebutate—Infection—Sunitinib—kidney cancer	0.00105	0.00651	CcSEcCtD
Ingenol Mebutate—Erythema—Gemcitabine—kidney cancer	0.00104	0.00645	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Sunitinib—kidney cancer	0.00104	0.00643	CcSEcCtD
Ingenol Mebutate—Headache—Pazopanib—kidney cancer	0.001	0.00623	CcSEcCtD
Ingenol Mebutate—Infection—Dactinomycin—kidney cancer	0.000994	0.00617	CcSEcCtD
Ingenol Mebutate—Eye disorder—Paclitaxel—kidney cancer	0.000934	0.00579	CcSEcCtD
Ingenol Mebutate—Infestation NOS—Capecitabine—kidney cancer	0.000913	0.00567	CcSEcCtD
Ingenol Mebutate—Infestation—Capecitabine—kidney cancer	0.000913	0.00567	CcSEcCtD
Ingenol Mebutate—Infection—Vincristine—kidney cancer	0.000888	0.00551	CcSEcCtD
Ingenol Mebutate—Conjunctivitis—Capecitabine—kidney cancer	0.000888	0.00551	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Vincristine—kidney cancer	0.000876	0.00544	CcSEcCtD
Ingenol Mebutate—Erythema—Paclitaxel—kidney cancer	0.00087	0.0054	CcSEcCtD
Ingenol Mebutate—Eye pain—Doxorubicin—kidney cancer	0.000846	0.00525	CcSEcCtD
Ingenol Mebutate—Infection—Gemcitabine—kidney cancer	0.000842	0.00523	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Gemcitabine—kidney cancer	0.000831	0.00516	CcSEcCtD
Ingenol Mebutate—Headache—Vinblastine—kidney cancer	0.000796	0.00494	CcSEcCtD
Ingenol Mebutate—Headache—Everolimus—kidney cancer	0.000792	0.00492	CcSEcCtD
Ingenol Mebutate—Eye disorder—Capecitabine—kidney cancer	0.000766	0.00475	CcSEcCtD
Ingenol Mebutate—Headache—Erlotinib—kidney cancer	0.000765	0.00474	CcSEcCtD
Ingenol Mebutate—Erythema—Capecitabine—kidney cancer	0.000714	0.00443	CcSEcCtD
Ingenol Mebutate—Infection—Paclitaxel—kidney cancer	0.000705	0.00438	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Paclitaxel—kidney cancer	0.000696	0.00432	CcSEcCtD
Ingenol Mebutate—Headache—Sorafenib—kidney cancer	0.000688	0.00427	CcSEcCtD
Ingenol Mebutate—Nasopharyngitis—Doxorubicin—kidney cancer	0.000683	0.00424	CcSEcCtD
Ingenol Mebutate—Headache—Sunitinib—kidney cancer	0.000662	0.00411	CcSEcCtD
Ingenol Mebutate—Infestation NOS—Doxorubicin—kidney cancer	0.000589	0.00365	CcSEcCtD
Ingenol Mebutate—Infestation—Doxorubicin—kidney cancer	0.000589	0.00365	CcSEcCtD
Ingenol Mebutate—Infection—Capecitabine—kidney cancer	0.000579	0.00359	CcSEcCtD
Ingenol Mebutate—Conjunctivitis—Doxorubicin—kidney cancer	0.000572	0.00355	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Capecitabine—kidney cancer	0.000571	0.00354	CcSEcCtD
Ingenol Mebutate—Headache—Vincristine—kidney cancer	0.00056	0.00347	CcSEcCtD
Ingenol Mebutate—Headache—Gemcitabine—kidney cancer	0.000531	0.0033	CcSEcCtD
Ingenol Mebutate—Eye disorder—Doxorubicin—kidney cancer	0.000494	0.00306	CcSEcCtD
Ingenol Mebutate—Erythema—Doxorubicin—kidney cancer	0.00046	0.00285	CcSEcCtD
Ingenol Mebutate—Headache—Paclitaxel—kidney cancer	0.000445	0.00276	CcSEcCtD
Ingenol Mebutate—Infection—Doxorubicin—kidney cancer	0.000373	0.00231	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Doxorubicin—kidney cancer	0.000368	0.00228	CcSEcCtD
Ingenol Mebutate—Headache—Capecitabine—kidney cancer	0.000365	0.00226	CcSEcCtD
Ingenol Mebutate—Headache—Doxorubicin—kidney cancer	0.000235	0.00146	CcSEcCtD
Ingenol Mebutate—PRKCA—Integrated Pancreatic Cancer Pathway—PIK3CA—kidney cancer	9.76e-05	0.000151	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Gene Expression—PSMD7—kidney cancer	9.71e-05	0.00015	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—CRABP1—kidney cancer	9.69e-05	0.00015	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—kidney cancer	9.66e-05	0.000149	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by Wnt—CTNNB1—kidney cancer	9.47e-05	0.000146	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Integrated Pancreatic Cancer Pathway—TP53—kidney cancer	9.44e-05	0.000146	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Hemostasis—MAPK3—kidney cancer	9.44e-05	0.000146	CbGpPWpGaD
Ingenol Mebutate—PRKCA—NGF signalling via TRKA from the plasma membrane—PIK3CA—kidney cancer	9.19e-05	0.000142	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Disease—HIF1A—kidney cancer	9.17e-05	0.000142	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Disease—TSC2—kidney cancer	9.15e-05	0.000141	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling by GPCR—POMC—kidney cancer	9.12e-05	0.000141	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—PSMD7—kidney cancer	9.02e-05	0.000139	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—ITPR2—kidney cancer	9.01e-05	0.000139	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Hemostasis—MAPK1—kidney cancer	8.98e-05	0.000139	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—kidney cancer	8.88e-05	0.000137	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—AKAP13—kidney cancer	8.86e-05	0.000137	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—CASP2—kidney cancer	8.86e-05	0.000137	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—PAK1—kidney cancer	8.77e-05	0.000135	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Immune System—KIT—kidney cancer	8.75e-05	0.000135	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Gene Expression—JUNB—kidney cancer	8.72e-05	0.000135	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Platelet activation, signaling and aggregation—PIK3CA—kidney cancer	8.69e-05	0.000134	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Innate Immune System—KIT—kidney cancer	8.63e-05	0.000133	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by NGF—MAPK3—kidney cancer	8.56e-05	0.000132	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—IFNA1—kidney cancer	8.55e-05	0.000132	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Innate Immune System—MAPK3—kidney cancer	8.5e-05	0.000131	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Hemostasis—KRAS—kidney cancer	8.48e-05	0.000131	CbGpPWpGaD
Ingenol Mebutate—PRKCA—M Phase—MAPK3—kidney cancer	8.35e-05	0.000129	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Neuronal System—MAPK1—kidney cancer	8.31e-05	0.000128	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—ACHE—kidney cancer	8.22e-05	0.000127	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—GSTT1—kidney cancer	8.22e-05	0.000127	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Cell Cycle, Mitotic—CDKN2A—kidney cancer	8.21e-05	0.000127	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—EGR1—kidney cancer	8.2e-05	0.000127	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—SLC2A1—kidney cancer	8.15e-05	0.000126	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by NGF—MAPK1—kidney cancer	8.14e-05	0.000126	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—GRB7—kidney cancer	8.1e-05	0.000125	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—JUNB—kidney cancer	8.09e-05	0.000125	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Innate Immune System—MAPK1—kidney cancer	8.09e-05	0.000125	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Disease—APC—kidney cancer	8.08e-05	0.000125	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Disease—KIT—kidney cancer	8.08e-05	0.000125	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—IGF2—kidney cancer	8.07e-05	0.000125	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Immune System—CDH1—kidney cancer	8.05e-05	0.000124	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—CDKN2B—kidney cancer	8.03e-05	0.000124	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—IFNA2—kidney cancer	7.96e-05	0.000123	CbGpPWpGaD
Ingenol Mebutate—PRKCA—M Phase—MAPK1—kidney cancer	7.94e-05	0.000123	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—IGF1R—kidney cancer	7.8e-05	0.00012	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Hemostasis—PIK3CA—kidney cancer	7.79e-05	0.00012	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—SCARB1—kidney cancer	7.78e-05	0.00012	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—PTGS1—kidney cancer	7.7e-05	0.000119	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by NGF—KRAS—kidney cancer	7.69e-05	0.000119	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by Wnt—MYC—kidney cancer	7.67e-05	0.000118	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Mitotic M-M/G1 phases—MAPK3—kidney cancer	7.65e-05	0.000118	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Innate Immune System—KRAS—kidney cancer	7.64e-05	0.000118	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Disease—BRAF—kidney cancer	7.59e-05	0.000117	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—PSMD7—kidney cancer	7.55e-05	0.000117	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Hemostasis—TP53—kidney cancer	7.54e-05	0.000116	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—ITPR2—kidney cancer	7.53e-05	0.000116	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Hemostasis—RAF1—kidney cancer	7.52e-05	0.000116	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling by GPCR—RAF1—kidney cancer	7.52e-05	0.000116	CbGpPWpGaD
Ingenol Mebutate—PRKCD—GPCR downstream signaling—IL2—kidney cancer	7.42e-05	0.000115	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Cell Cycle—CDKN2A—kidney cancer	7.34e-05	0.000113	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Mitotic M-M/G1 phases—MAPK1—kidney cancer	7.28e-05	0.000112	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Cell Cycle, Mitotic—CDKN1B—kidney cancer	7.27e-05	0.000112	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—BCHE—kidney cancer	7.16e-05	0.000111	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Gene Expression—CDKN2B—kidney cancer	7.1e-05	0.00011	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—SLC5A5—kidney cancer	7.07e-05	0.000109	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by NGF—PIK3CA—kidney cancer	7.07e-05	0.000109	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Innate Immune System—PIK3CA—kidney cancer	7.02e-05	0.000108	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Cell Cycle, Mitotic—CCND1—kidney cancer	6.94e-05	0.000107	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Immune System—RAF1—kidney cancer	6.87e-05	0.000106	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Immune System—RELA—kidney cancer	6.84e-05	0.000106	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—CTNNA1—kidney cancer	6.83e-05	0.000105	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—SLC2A1—kidney cancer	6.83e-05	0.000105	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Immune System—ERBB2—kidney cancer	6.79e-05	0.000105	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—HSPB1—kidney cancer	6.79e-05	0.000105	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—EIF4EBP1—kidney cancer	6.79e-05	0.000105	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Innate Immune System—RAF1—kidney cancer	6.77e-05	0.000105	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Hemostasis—IL2—kidney cancer	6.74e-05	0.000104	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Innate Immune System—RELA—kidney cancer	6.74e-05	0.000104	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling by GPCR—IL2—kidney cancer	6.74e-05	0.000104	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Immune System—MTOR—kidney cancer	6.7e-05	0.000104	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Innate Immune System—ERBB2—kidney cancer	6.7e-05	0.000103	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—CD8A—kidney cancer	6.69e-05	0.000103	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Immune System—CD4—kidney cancer	6.69e-05	0.000103	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Innate Immune System—MTOR—kidney cancer	6.61e-05	0.000102	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Innate Immune System—CD4—kidney cancer	6.6e-05	0.000102	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—CDKN2B—kidney cancer	6.59e-05	0.000102	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Cell Cycle—CDKN1B—kidney cancer	6.5e-05	0.0001	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—HIF1A—kidney cancer	6.42e-05	9.92e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—TSC2—kidney cancer	6.41e-05	9.89e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Disease—RAF1—kidney cancer	6.34e-05	9.79e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—PSMD7—kidney cancer	6.31e-05	9.75e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—TSC1—kidney cancer	6.31e-05	9.75e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—ANXA1—kidney cancer	6.31e-05	9.75e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Immune System—CDKN1B—kidney cancer	6.29e-05	9.72e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Disease—ERBB2—kidney cancer	6.27e-05	9.69e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Cell Cycle—CCND1—kidney cancer	6.2e-05	9.58e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Innate Immune System—CDKN1B—kidney cancer	6.2e-05	9.58e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Disease—MTOR—kidney cancer	6.19e-05	9.56e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Disease—CD4—kidney cancer	6.18e-05	9.54e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Immune System—IL2—kidney cancer	6.16e-05	9.51e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—KDR—kidney cancer	6.14e-05	9.48e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Disease—PTGS2—kidney cancer	6.13e-05	9.47e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—FLT1—kidney cancer	6.11e-05	9.44e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Immune System—JUN—kidney cancer	5.99e-05	9.25e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Immune System—CTNNB1—kidney cancer	5.94e-05	9.18e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Innate Immune System—JUN—kidney cancer	5.91e-05	9.12e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Innate Immune System—CTNNB1—kidney cancer	5.86e-05	9.05e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Disease—CDKN1B—kidney cancer	5.81e-05	8.97e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Immune System—PTEN—kidney cancer	5.79e-05	8.95e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—GPCR downstream signaling—POMC—kidney cancer	5.77e-05	8.9e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Hemostasis—VEGFA—kidney cancer	5.73e-05	8.85e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Cell Cycle, Mitotic—MAPK3—kidney cancer	5.72e-05	8.84e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Innate Immune System—PTEN—kidney cancer	5.71e-05	8.82e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—GSTP1—kidney cancer	5.69e-05	8.8e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—TSC2—kidney cancer	5.69e-05	8.79e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—JUNB—kidney cancer	5.67e-05	8.75e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—PAK1—kidney cancer	5.67e-05	8.75e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—KIT—kidney cancer	5.66e-05	8.74e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—APC—kidney cancer	5.66e-05	8.74e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Cell Cycle, Mitotic—MYC—kidney cancer	5.57e-05	8.6e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Disease—CTNNB1—kidney cancer	5.49e-05	8.48e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Cell Cycle, Mitotic—MAPK1—kidney cancer	5.45e-05	8.41e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Hemostasis—MAPK3—kidney cancer	5.42e-05	8.37e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling by GPCR—MAPK3—kidney cancer	5.42e-05	8.37e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—ABCB1—kidney cancer	5.39e-05	8.33e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—POMC—kidney cancer	5.39e-05	8.32e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Disease—PTEN—kidney cancer	5.35e-05	8.26e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—BRAF—kidney cancer	5.32e-05	8.21e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—HIF1A—kidney cancer	5.27e-05	8.13e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—TSC2—kidney cancer	5.25e-05	8.11e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by GPCR—POMC—kidney cancer	5.24e-05	8.09e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—GSTM1—kidney cancer	5.23e-05	8.08e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Hemostasis—MAPK1—kidney cancer	5.16e-05	7.97e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling by GPCR—MAPK1—kidney cancer	5.16e-05	7.96e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Cell Cycle—MAPK3—kidney cancer	5.12e-05	7.9e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—KIT—kidney cancer	5.03e-05	7.76e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Cell Cycle—MYC—kidney cancer	4.98e-05	7.69e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—CYP1A1—kidney cancer	4.96e-05	7.66e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Immune System—MAPK3—kidney cancer	4.95e-05	7.65e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—GPCR downstream signaling—PIK3CA—kidney cancer	4.93e-05	7.61e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Gene Expression—MAPK3—kidney cancer	4.92e-05	7.6e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Innate Immune System—MAPK3—kidney cancer	4.88e-05	7.54e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Hemostasis—KRAS—kidney cancer	4.87e-05	7.53e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling by GPCR—KRAS—kidney cancer	4.87e-05	7.52e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Cell Cycle—MAPK1—kidney cancer	4.87e-05	7.52e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Gene Expression—MYC—kidney cancer	4.79e-05	7.39e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Immune System—MAPK1—kidney cancer	4.71e-05	7.27e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Innate Immune System—MAPK1—kidney cancer	4.64e-05	7.17e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—KIT—kidney cancer	4.64e-05	7.17e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—APC—kidney cancer	4.64e-05	7.17e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—IGF2—kidney cancer	4.63e-05	7.16e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—CDH1—kidney cancer	4.63e-05	7.14e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—CDKN2B—kidney cancer	4.61e-05	7.13e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Disease—MAPK3—kidney cancer	4.57e-05	7.06e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—IGF1R—kidney cancer	4.48e-05	6.92e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Hemostasis—PIK3CA—kidney cancer	4.48e-05	6.91e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling by GPCR—PIK3CA—kidney cancer	4.47e-05	6.91e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Immune System—KRAS—kidney cancer	4.45e-05	6.87e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Disease—MYC—kidney cancer	4.45e-05	6.87e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—RAF1—kidney cancer	4.44e-05	6.86e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—RELA—kidney cancer	4.42e-05	6.83e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—ERBB2—kidney cancer	4.39e-05	6.78e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Innate Immune System—KRAS—kidney cancer	4.39e-05	6.78e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—BRAF—kidney cancer	4.36e-05	6.74e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Disease—MAPK1—kidney cancer	4.35e-05	6.72e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—MTOR—kidney cancer	4.33e-05	6.69e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Hemostasis—TP53—kidney cancer	4.33e-05	6.69e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by GPCR—RAF1—kidney cancer	4.32e-05	6.67e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—GPCR downstream signaling—IL2—kidney cancer	4.26e-05	6.58e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Disease—KRAS—kidney cancer	4.11e-05	6.34e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Immune System—PIK3CA—kidney cancer	4.09e-05	6.31e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Cell Cycle—TP53—kidney cancer	4.09e-05	6.31e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—CDKN1B—kidney cancer	4.07e-05	6.28e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Innate Immune System—PIK3CA—kidney cancer	4.03e-05	6.22e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—IL2—kidney cancer	3.98e-05	6.15e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—RAF1—kidney cancer	3.94e-05	6.09e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—RELA—kidney cancer	3.93e-05	6.06e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—ERBB2—kidney cancer	3.9e-05	6.03e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—CCND1—kidney cancer	3.88e-05	5.99e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—JUN—kidney cancer	3.87e-05	5.98e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by GPCR—IL2—kidney cancer	3.87e-05	5.98e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—MTOR—kidney cancer	3.85e-05	5.95e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—CD4—kidney cancer	3.84e-05	5.94e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—CTNNB1—kidney cancer	3.84e-05	5.94e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Disease—PIK3CA—kidney cancer	3.77e-05	5.83e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—PTEN—kidney cancer	3.75e-05	5.79e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—POMC—kidney cancer	3.7e-05	5.71e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—HIF1A—kidney cancer	3.69e-05	5.7e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—TSC2—kidney cancer	3.68e-05	5.68e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—RAF1—kidney cancer	3.64e-05	5.62e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—CDKN1B—kidney cancer	3.61e-05	5.58e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—ERBB2—kidney cancer	3.6e-05	5.56e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—MTOR—kidney cancer	3.56e-05	5.49e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—CD4—kidney cancer	3.55e-05	5.48e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—IL2—kidney cancer	3.54e-05	5.46e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—KDR—kidney cancer	3.53e-05	5.45e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—PTGS2—kidney cancer	3.52e-05	5.44e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—JUN—kidney cancer	3.44e-05	5.31e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—CTNNB1—kidney cancer	3.41e-05	5.27e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—VEGFA—kidney cancer	3.38e-05	5.23e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—CDKN1B—kidney cancer	3.34e-05	5.15e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—PTEN—kidney cancer	3.33e-05	5.14e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—KIT—kidney cancer	3.25e-05	5.02e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—APC—kidney cancer	3.25e-05	5.02e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—MAPK3—kidney cancer	3.2e-05	4.94e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—CTNNB1—kidney cancer	3.15e-05	4.87e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—MYC—kidney cancer	3.11e-05	4.81e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by GPCR—MAPK3—kidney cancer	3.11e-05	4.81e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—POMC—kidney cancer	3.09e-05	4.78e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—PTEN—kidney cancer	3.07e-05	4.74e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—BRAF—kidney cancer	3.05e-05	4.72e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—MAPK1—kidney cancer	3.05e-05	4.7e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by GPCR—MAPK1—kidney cancer	2.96e-05	4.57e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—PTGS2—kidney cancer	2.95e-05	4.56e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—KRAS—kidney cancer	2.88e-05	4.44e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—MAPK3—kidney cancer	2.84e-05	4.39e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—GPCR downstream signaling—PIK3CA—kidney cancer	2.83e-05	4.37e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Gene Expression—MAPK3—kidney cancer	2.83e-05	4.37e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by GPCR—KRAS—kidney cancer	2.8e-05	4.32e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Gene Expression—MYC—kidney cancer	2.75e-05	4.25e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—MAPK1—kidney cancer	2.71e-05	4.18e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—PIK3CA—kidney cancer	2.64e-05	4.08e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—MAPK3—kidney cancer	2.63e-05	4.05e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—PTEN—kidney cancer	2.57e-05	3.97e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by GPCR—PIK3CA—kidney cancer	2.57e-05	3.97e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—TP53—kidney cancer	2.56e-05	3.95e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—KRAS—kidney cancer	2.56e-05	3.95e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—MYC—kidney cancer	2.55e-05	3.94e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—RAF1—kidney cancer	2.55e-05	3.94e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—RELA—kidney cancer	2.54e-05	3.92e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—ERBB2—kidney cancer	2.52e-05	3.9e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—MAPK1—kidney cancer	2.5e-05	3.86e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—MTOR—kidney cancer	2.49e-05	3.85e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—KRAS—kidney cancer	2.36e-05	3.64e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—PIK3CA—kidney cancer	2.35e-05	3.63e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—CDKN1B—kidney cancer	2.34e-05	3.61e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—IL2—kidney cancer	2.29e-05	3.53e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—CCND1—kidney cancer	2.23e-05	3.44e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—JUN—kidney cancer	2.22e-05	3.44e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—CTNNB1—kidney cancer	2.21e-05	3.41e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—PIK3CA—kidney cancer	2.17e-05	3.35e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—PTEN—kidney cancer	2.15e-05	3.32e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—VEGFA—kidney cancer	1.94e-05	3e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—MAPK3—kidney cancer	1.84e-05	2.84e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—PIK3CA—kidney cancer	1.82e-05	2.8e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—MYC—kidney cancer	1.79e-05	2.76e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—MAPK1—kidney cancer	1.75e-05	2.7e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—KRAS—kidney cancer	1.65e-05	2.55e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—PIK3CA—kidney cancer	1.52e-05	2.34e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—TP53—kidney cancer	1.47e-05	2.27e-05	CbGpPWpGaD
